Equibles does not estimate personal net worth.
Get an email with a short summary when Johnson & Johnson publishes a filing, an earnings call transcript or a press release.
Get JNJ alertsJoe Wolk is recorded as CFO at Johnson & Johnson (JNJ). Joe Wolk has spoken on 14 earnings calls across 1 company, most recently for Johnson & Johnson on October 14, 2025. Johnson & Johnson is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Johnson & Johnson includes J. Wolk (CFO), D. E. Pinto (Board Member), Daniel Pinto (Board Member) and 7 others.
“The third quarter, we sustained momentum across our end market portfolio, delivering upon the heightened financial expectations we guided to last quarter. In Innovative Medicine, we continue to grow to the STELARA loss of exclusivity as we said we would.”
“Thanks, Jessica, not just for the transition now, but also for how well you have led the investor relations function the past few years. The investment community will miss you, but we look forward to seeing you in the lead finance role in innovative medicine.”
“In the third quarter, Johnson & Johnson delivered results that illustrate not only the breadth of the business, but our ability to consistently beat financial expectations.”
“Overall, Johnson & Johnson delivered solid top- and bottom-line growth, as well as free cash flow growth in the quarter. Our Innovative Medicine business made great progress in the second quarter.”
“This quarter's call marks a new era for Johnson & Johnson with a sharpened focus on Innovative Medicine and MedTech. What has remained consistent is our Credo and our commitment to patients.”
Drug Manufacturers - General · Healthcare
CFO
